Clinical Report: Single-Cell Transcriptomic Analysis Reveals Monocyte Reprogramming Dynamics During ALSS Treatment in Type B HBV-ACLF
Overview
This case study highlights the dynamic reprogramming of monocytes during artificial liver support system (ALSS) treatment in a patient with Type B HBV-related acute-on-chronic liver failure (ACLF). Notably, a distinct inflammatory monocyte subpopulation was identified, which decreased in proportion and inflammatory activity following ALSS therapy.
Background
Hepatitis B virus-related ACLF is a critical condition marked by severe liver dysfunction and systemic inflammation, leading to high mortality rates. Monocytes are pivotal in the inflammatory response associated with HBV-ACLF, making their study essential for understanding disease progression and treatment efficacy. ALSS therapy represents a potential bridge to liver transplantation and may mitigate the inflammatory cascade in these patients.
Data Highlights
Single-cell RNA sequencing revealed significant transcriptomic changes in monocytes during ALSS treatment, with a notable decrease in the inflammatory Mono4 subpopulation.
Key Findings
Monocytes exhibited the most pronounced transcriptomic alterations among peripheral blood mononuclear cells (PBMCs).
A distinct inflammatory monocyte subpopulation (Mono4) was characterized by upregulated mitochondrial genes and inflammatory factors.
ALSS treatment resulted in a decreased proportion of Mono4 and reduced its pro-inflammatory secretory profile.
Pseudotime analysis indicated a differentiation trajectory from classical monocytes to Mono4, which diminished with treatment.
Bulk RNA-seq confirmed the monocyte-centric immune landscape in the context of HBV-ACLF.
Clinical Implications
The findings suggest that monitoring monocyte populations, particularly Mono4, may provide insights into the inflammatory status of patients undergoing ALSS treatment for HBV-ACLF. This could inform therapeutic strategies and improve patient management in this challenging clinical scenario.
Conclusion
This case study underscores the potential of ALSS therapy to reprogram monocyte responses in HBV-ACLF, highlighting the importance of targeted immunomodulation in managing systemic inflammation.
